200 related articles for article (PubMed ID: 36006428)
61. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.
Jorgov L; Montravers F; Balogova S; Ragu C; Pacquement H; Leblanc T; Abbou S; Ducou-Lepointe H; Landman-Parker J; Talbot JN
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1220-30. PubMed ID: 26660144
[TBL] [Abstract][Full Text] [Related]
62. Pretreatment
Dissaux G; Visvikis D; Da-Ano R; Pradier O; Chajon E; Barillot I; Duvergé L; Masson I; Abgral R; Santiago Ribeiro MJ; Devillers A; Pallardy A; Fleury V; Mahé MA; De Crevoisier R; Hatt M; Schick U
J Nucl Med; 2020 Jun; 61(6):814-820. PubMed ID: 31732678
[TBL] [Abstract][Full Text] [Related]
63. Prognostic Value of
Carlier T; Frécon G; Mateus D; Rizkallah M; Kraeber-Bodéré F; Kanoun S; Blanc-Durand P; Itti E; Le Gouill S; Casasnovas RO; Bodet-Milin C; Bailly C
J Nucl Med; 2024 Jan; 65(1):156-162. PubMed ID: 37945379
[TBL] [Abstract][Full Text] [Related]
64. TAC y PET/TC con 18-FDG para evaluar la respuesta al tratamiento en linfoma de Hodgkin y no Hodgkin.
Vargas-Partida T; Hernández-Cruz M; Ruiz-Eng R; Montiel-Jarquín ÁJ; Vázquez-Cruz E; López-Colombo A
Gac Med Mex; 2019; 155(4):386-390. PubMed ID: 31486785
[TBL] [Abstract][Full Text] [Related]
65. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
[TBL] [Abstract][Full Text] [Related]
66. Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival.
Dai N; Liu H; Deng S; Sang S; Wu Y
Technol Cancer Res Treat; 2021; 20():15330338211056478. PubMed ID: 34806464
[No Abstract] [Full Text] [Related]
67. Performance of CT Compared with
Mokrane FZ; Chen A; Schwartz LH; Morschhauser F; Stamatoullas A; Schiano de Colella JM; Vercellino L; Casasnovas O; Chauchet A; Delmer A; Nicolas-Virelizier E; Ghesquières H; Moles-Moreau MP; Schmitt A; Duléry R; Bouabdallah K; Borel C; Touati M; Deau-Fischer B; Peyrade F; Seban RD; Manson G; Houot R; Dercle L
Radiology; 2020 Jun; 295(3):651-661. PubMed ID: 32286191
[TBL] [Abstract][Full Text] [Related]
68. Prediction of Overall Survival and Progression-Free Survival by the
Zhou Y; Ma XL; Pu LT; Zhou RF; Ou XJ; Tian R
Contrast Media Mol Imaging; 2019; 2019():5963607. PubMed ID: 31777473
[No Abstract] [Full Text] [Related]
69. Radiomic Analysis of Positron-Emission Tomography and Computed Tomography Images to Differentiate between Multiple Myeloma and Skeletal Metastases.
Mannam P; Murali A; Gokulakrishnan P; Venkatachalapathy E; Venkata Sai PM
Indian J Nucl Med; 2022; 37(3):217-226. PubMed ID: 36686312
[TBL] [Abstract][Full Text] [Related]
70.
Li P; Wang X; Xu C; Liu C; Zheng C; Fulham MJ; Feng D; Wang L; Song S; Huang G
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1116-1126. PubMed ID: 31982990
[TBL] [Abstract][Full Text] [Related]
71. Pre-treatment
Ahn HK; Lee H; Kim SG; Hyun SH
Clin Radiol; 2019 Jun; 74(6):467-473. PubMed ID: 30898382
[TBL] [Abstract][Full Text] [Related]
72. Molecular subtype classification of breast cancer using established radiomic signature models based on
Liu J; Bian H; Zhang Y; Gao Y; Yin G; Wang Z; Li X; Ma W; Xu W
Front Biosci (Landmark Ed); 2021 Aug; 26(9):475-484. PubMed ID: 34590460
[No Abstract] [Full Text] [Related]
73. Development and validation of an
Wang H; Zhao S; Li L; Tian R
Eur Radiol; 2020 Oct; 30(10):5578-5587. PubMed ID: 32435928
[TBL] [Abstract][Full Text] [Related]
74. Machine learning predictive performance evaluation of conventional and fuzzy radiomics in clinical cancer imaging cohorts.
Grahovac M; Spielvogel CP; Krajnc D; Ecsedi B; Traub-Weidinger T; Rasul S; Kluge K; Zhao M; Li X; Hacker M; Haug A; Papp L
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1607-1620. PubMed ID: 36738311
[TBL] [Abstract][Full Text] [Related]
75. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
76. Prognostic Value of 2-Deoxy-2-[
Dai N; Zhou Y; Deng S; Sang S; Wu Y
Contrast Media Mol Imaging; 2021; 2021():5510825. PubMed ID: 33958977
[TBL] [Abstract][Full Text] [Related]
77. Application of Machine Learning Analyses Using Clinical and [
Kawaji K; Nakajo M; Shinden Y; Jinguji M; Tani A; Hirahara D; Kitazono I; Ohtsuka T; Yoshiura T
Mol Imaging Biol; 2023 Oct; 25(5):923-934. PubMed ID: 37193804
[TBL] [Abstract][Full Text] [Related]
78. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
79. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
van Heek L; Stuka C; Kaul H; Müller H; Mettler J; Hitz F; Baues C; Fuchs M; Borchmann P; Engert A; Dietlein M; Voltin CA; Kobe C
BMC Cancer; 2022 Jun; 22(1):672. PubMed ID: 35717166
[TBL] [Abstract][Full Text] [Related]
80. Ability of final PET/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma.
Galvez-Carvajal L; Quero C; Casanova M; Díaz C; Chícharo JR; Espeso M; Medina Á; Ramos I; Alba E; Rueda A
Int J Hematol; 2022 Jan; 115(1):54-60. PubMed ID: 34546542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
